A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Owen Mumford Achieves B Corp Certification

What To Know

  • Owen Mumford, which established its sustainability program in 2014 and has formally committed to the UN's Sustainable Development Goals (SDGs), now joins a highly respected community of for-profit businesses that are applying growth and profit to the positive gain of the environment and external communities, as well as employees.
  • Owen Mumford has pioneered the design and manufacture of medical devices such as self-injection, blood sampling, and drug delivery for almost 70 years and is the first such company to become part of the B Corp community.

Owen Mumford, a global leader in the design, manufacture, and advancement of medical devices, today announced it has been awarded B Corp certification after demonstrating strict compliance to the rigorous requirements of this hard-to-achieve, globally-recognized mark.

Owen Mumford, which established its sustainability program in 2014 and has formally committed to the UN’s Sustainable Development Goals (SDGs), now joins a highly respected community of for-profit businesses that are applying growth and profit to the positive gain of the environment and external communities, as well as employees.

B Corp is the standard for a new generation of aspirational brands who are helping to define the future of business in a responsible way. There are now 4,010 B Corps in 77 countries and 153 industries, and over 100,000 companies manage their impact with the B Impact Assessment and the SDG Action Manager. The B Corp community in the UK, representing a broad cross-section of industries and sizes, comprises over 400 companies.

B Corp certification assesses five areas of impact: governance, community, workers, environment and customers. “Our social and environmental responsibilities have always been high on the agenda at Owen Mumford,” said Jarl Severn, CEO at Owen Mumford. “Submitting ourselves to the rigorous process of B Corp certification is a natural development of our core principles. Companies like ours that operate in the medical sector are used to the demands of a tightly regulated environment. We believe that it is not enough simply to state ethical and environmental aspirations, but it is also critical to achieving a recognized certification. After all, our marketplaces are reliant on top ethical standards to protect environments, professionals and patients. B Corp provides a solid benchmark for continually improving what we do in our business, in the global communities that we are part of and the ones where can make a positive impact.”

Owen Mumford has pioneered the design and manufacture of medical devices such as self-injection, blood sampling, and drug delivery for almost 70 years and is the first such company to become part of the B Corp community. This milestone firmly underscores its commitment to making a positive difference on social and environmental impact.

Kate Sandle, Director of Programmes and Engagement of B Lab UK, says “We are delighted to welcome Owen Mumford to the B Corp community. This is a movement of companies who are committed to changing how the business operates and believe business really can be a force for good. We know that Owen Mumford is going to be a fantastic addition to the community and will continue driving the conversation forward. Welcoming Owen Mumford is an exciting moment because it has an opportunity to lead the way within the medical device industry.”

B Corp certification must be renewed every three years to ensure continuing compliance to the stringent requirements.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.
SABIC advises the project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium.

By using this website you agree to accept Medical Device News Magazine Privacy Policy